SIC
VTGN icon

SJS Investment Consulting’s VistaGen Therapeutics VTGN Stock Holding History

SJS Investment Consulting’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$250 – 1670
2025
Q1 		$250 Hold
100
– – ﹤0.01% 1417
2024
Q4 		$295 Hold
100
– – ﹤0.01% 1395
2024
Q3 		$301 Hold
100
– – ﹤0.01% 1448
2024
Q2 		$348 Buy
+100
New +$433 ﹤0.01% 1402

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SJS Investment Consulting's VTGN Position: Q2 2025 in Review

SJS Investment Consulting sold out of VistaGen Therapeutics (VTGN) in Q2 2025, closing a stake of 100 shares — an estimated $250 sold.

SJS Investment Consulting first reported a position in VTGN in Q2 2024 and held it in 4 quarters. The position peaked at $348 in Q2 2024. 51 funds tracked by Wall St. Rank hold VTGN as of Q2 2025.

  • SJS Investment Consulting reported no remaining VistaGen Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SJS Investment Consulting sold 100 VistaGen Therapeutics shares in Q2 2025, an estimated $250.
  • SJS Investment Consulting first reported a position in VistaGen Therapeutics in Q2 2024 and held it in 4 quarters.
  • SJS Investment Consulting's VistaGen Therapeutics position peaked at $348 in Q2 2024.
  • 51 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2025.

Based on SJS Investment Consulting's 13F filing for Q2 2025, filed 15 Jul 2025.